FDA Approves Neoadjuvant Nivolumab/Chemo for Early-Stage NSCLC

The pathologic complete response rate was 24% versus 2.2% with chemotherapy alone.

Related Keywords

Mark Awad ,Drug Administration ,Dana Farber Cancer Institute ,Bristol Myers Squibb ,Lung Cancer ,Ung Carcinoma ,Ancer Lung ,Non Small Cell Lung Cancer ,Nsclc ,Cancer ,Alignant Neoplasia ,Arcinoma ,Chemotherapy ,Neoadjuvant ,Combination Chemotherapy ,Biologic Therapy In Cancer ,Iological Therapy In Cancer ,Iologics Cancer ,Biologic Therapy ,Platinum ,Pneumonia ,Nausea ,Constipation ,Fatigue ,Clinical Research ,Clinical Trials ,Linical Studies ,Medical Literature ,Books ,Textbooks ,O ,